CN110545850A - 可释放的缀合物 - Google Patents

可释放的缀合物 Download PDF

Info

Publication number
CN110545850A
CN110545850A CN201880014422.0A CN201880014422A CN110545850A CN 110545850 A CN110545850 A CN 110545850A CN 201880014422 A CN201880014422 A CN 201880014422A CN 110545850 A CN110545850 A CN 110545850A
Authority
CN
China
Prior art keywords
compound
formula
group
hydrochloride
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880014422.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·克维亚特科夫斯基
C·松德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quiapaig Pharmaceutical Co
Original Assignee
Quiapaig Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quiapaig Pharmaceutical Co filed Critical Quiapaig Pharmaceutical Co
Publication of CN110545850A publication Critical patent/CN110545850A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201880014422.0A 2017-03-10 2018-03-10 可释放的缀合物 Pending CN110545850A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762469989P 2017-03-10 2017-03-10
US62/469,989 2017-03-10
US201762564820P 2017-09-28 2017-09-28
US62/564,820 2017-09-28
PCT/IB2018/051579 WO2018163131A1 (en) 2017-03-10 2018-03-10 Releasable conjugates

Publications (1)

Publication Number Publication Date
CN110545850A true CN110545850A (zh) 2019-12-06

Family

ID=61764062

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880014422.0A Pending CN110545850A (zh) 2017-03-10 2018-03-10 可释放的缀合物

Country Status (11)

Country Link
US (2) US11786599B2 (enExample)
EP (2) EP3592393B1 (enExample)
JP (2) JP7152408B2 (enExample)
KR (1) KR20190125310A (enExample)
CN (1) CN110545850A (enExample)
AU (2) AU2018231832A1 (enExample)
BR (1) BR112019017103A2 (enExample)
CA (1) CA3051173A1 (enExample)
DK (1) DK3592393T3 (enExample)
SI (1) SI3592393T1 (enExample)
WO (1) WO2018163131A1 (enExample)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110946844A (zh) * 2019-12-11 2020-04-03 正大制药（青岛）有限公司 一种含有艾地骨化醇的复方控释制剂
CN111175387A (zh) * 2018-11-13 2020-05-19 成都康弘药业集团股份有限公司 一种米那普仑异构体的检测方法
CN112168820A (zh) * 2019-07-05 2021-01-05 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
CN112316156A (zh) * 2020-10-27 2021-02-05 四川大学 具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
CN112402620A (zh) * 2020-12-07 2021-02-26 南开大学 肿瘤微环境还原响应性的纳米药物及其制备方法
CN112457383A (zh) * 2020-12-16 2021-03-09 南京盖斯夫医药科技有限公司 一种多肽、制备方法及其医药用途
CN112516285A (zh) * 2020-12-18 2021-03-19 中南大学 一种预防或治疗缺血/再灌注损伤的药物组合物及应用
CN112574272A (zh) * 2020-12-25 2021-03-30 中国医学科学院药用植物研究所 一种灵芝酸a衍生物的制备及其应用
CN112955216A (zh) * 2018-09-12 2021-06-11 奎亚培格制药公司 可释放glp-1缀合物
CN113456824A (zh) * 2020-03-31 2021-10-01 四川大学华西医院 一种抗肿瘤载药纳米复合材料
CN114516921A (zh) * 2021-02-05 2022-05-20 华南理工大学 基于单链抗体片段的融合蛋白、纳米组装体及其制备方法和应用
CN114617876A (zh) * 2022-01-28 2022-06-14 四川大学华西医院 一种抗肿瘤联合用药物
CN114886817A (zh) * 2022-06-02 2022-08-12 杭州配方师科技有限公司 一种弗来歇氏柳叶菜和酵母菌锌发酵复合物、制备方法及应用
CN118324849A (zh) * 2022-12-22 2024-07-12 四川大学华西医院 一种抗菌肽及其制备方法和用途
CN119613558A (zh) * 2024-12-12 2025-03-14 东北农业大学 一种抗磺胺嘧啶纳米抗体及其应用
CN119709677A (zh) * 2024-10-28 2025-03-28 皖西学院 一种糖基转移酶及其在制备金线莲苷中的应用
CN120531651A (zh) * 2025-07-29 2025-08-26 清枫链食苏打饮品(吉林)有限公司 人参提取物、制备方法及其在美白嫩肤祛皱产品中的应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545850A (zh) * 2017-03-10 2019-12-06 奎亚培格制药公司 可释放的缀合物
BR112020015071A2 (pt) 2018-03-09 2021-01-05 Quiapeg Pharmaceuticals Ab Conjugados de anticorpos liberáveis
US10768173B1 (en) 2019-09-06 2020-09-08 Element Biosciences, Inc. Multivalent binding composition for nucleic acid analysis
US11287422B2 (en) 2019-09-23 2022-03-29 Element Biosciences, Inc. Multivalent binding composition for nucleic acid analysis
KR102398574B1 (ko) 2019-10-10 2022-05-13 주식회사 엘지에너지솔루션 전지 모듈 및 이를 포함하는 전지 팩
JP2023513895A (ja) * 2020-02-03 2023-04-04 スノーレトックス リミテッド 組成物及び方法
WO2022029178A1 (en) 2020-08-05 2022-02-10 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
CN112138170B (zh) * 2020-09-28 2022-05-20 广东药科大学 一种预防顺铂药源性聋的缀合物及其制备方法和应用
CN112999196B (zh) * 2021-03-03 2023-04-28 西安医学院 用于长效稳定释放的吗替麦考酚酯纳米制剂及其制备方法
CN113133989B (zh) * 2021-03-09 2023-04-25 西安医学院 一种用于抗结核药物利福平的长效制剂及制备方法
EP4539887A1 (en) * 2022-06-16 2025-04-23 Merck Sharp & Dohme LLC Interleukin-2 prodrugs
KR102623104B1 (ko) * 2023-08-23 2024-01-11 에프아이씨씨주식회사 보툴리눔톡신 결합체와 줄기세포 엑소좀 복합체를 유효성분으로 함유하는 피부 재생 및 주름 개선용 화장료 조성물 및 그의 제조 방법
WO2025257419A1 (en) * 2024-06-13 2025-12-18 4Moving Biotech Glp-1 receptor agonist compounds for treating a proliferative synovial disorder
CN118415977B (zh) * 2024-07-03 2024-08-23 山东新时代药业有限公司 一种米力农注射剂及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105813653A (zh) * 2013-12-19 2016-07-27 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200130A (en) * 1878-02-12 Improvement in joining sheet metal to wire-cloth for the construction of fly-traps
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
CZ290670B6 (cs) 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US5830600A (en) * 1996-05-24 1998-11-03 Sri International Nonflammable/self-extinguishing electrolytes for batteries
JPH10175987A (ja) 1996-12-13 1998-06-30 Nof Corp 重合性基含有有機リン酸エステル化合物およびその製造方法
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5922897A (en) 1998-05-29 1999-07-13 Xerox Corporation Surfactant processes
JP2000212191A (ja) * 1999-01-26 2000-08-02 Sankyo Co Ltd リン酸誘導体
US20030165849A1 (en) 2000-11-28 2003-09-04 Biliang Zhang Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of RNA
US6320041B1 (en) 2001-04-13 2001-11-20 Trilink Biotechnologies, Inc. Pre-activated carbonyl linkers for the modification of oligonucleotides
US6743905B2 (en) 2001-04-16 2004-06-01 Applera Corporation Mobility-modified nucleobase polymers and methods of using same
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20100240730A1 (en) 2002-02-20 2010-09-23 Merck Sharp And Dohme Corp. RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CA2515889C (en) 2003-02-14 2015-07-14 Quanta Biodesign, Ltd. The selective and specific preparation of discrete peg compounds
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005077966A1 (en) 2004-02-10 2005-08-25 Isis Pharmaceuticals, Inc. Substituted pixyl protecting groups for oligonucleotide synthesis
HUE045882T2 (hu) 2004-03-23 2020-01-28 Ascendis Pharma Gmbh Polimer prodrug önmagát lehasító linkerrel
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
US20060063147A1 (en) 2004-09-21 2006-03-23 Chernov Boris K Omega-amino-PEG-phosphoramidites and conjugates thereof
TW200612993A (en) 2004-10-08 2006-05-01 Alza Corp Lipopolymer conjugates
JP2009514814A (ja) 2005-10-21 2009-04-09 シナジェバ・バイオファーマ・コーポレイション グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
WO2007055789A2 (en) 2005-10-31 2007-05-18 Neose Technologies, Inc. Expression of soluble therapeutic proteins
WO2007059912A1 (en) 2005-11-23 2007-05-31 Roche Diagnostics Gmbh Polynucleotide labelling reagent
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
JP5140824B2 (ja) * 2006-04-19 2013-02-13 国立大学法人 東京大学 リゾホスファチジルスレオニンおよびその誘導体
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
MX2009004856A (es) 2006-11-09 2009-06-05 Alcon Res Ltd Matriz polimerica insoluble en agua para suministro de farmaco.
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
KR101647334B1 (ko) 2008-07-10 2016-08-10 세리나 쎄라퓨틱스, 인코포레이티드 불활성 말단기를 가진 폴리옥사졸린, 보호된 개시기로부터 제조된 폴리옥사졸린 및 그와 관련된 화합물
US8449872B2 (en) 2008-09-19 2013-05-28 Nektar Therapeutics Polymer conjugates of nesiritide peptides
TWI471137B (zh) 2009-05-20 2015-02-01 Biomarin Pharm Inc Ｃ型利鈉胜肽變異體
EP2459227B1 (en) 2009-07-31 2021-03-17 Ascendis Pharma A/S Prodrugs containing an aromatic amine connected by an amide bond to a carrier
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
CN103025165B (zh) 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释
EP2600897A2 (en) 2010-08-06 2013-06-12 The Regents of the University of Colorado, A Body Corporate Methods and compositions for the inhibition of fructokinase
US8846941B2 (en) 2010-12-13 2014-09-30 Quiapeg Ab Functionalized polymers
MX347361B (es) * 2011-07-19 2017-04-12 Wave Life Sciences Ltd Metodos para la sintesis de acidos nucleicos funcionalizados.
WO2013024053A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
EP3628332A1 (en) 2012-06-12 2020-04-01 QuiaPEG Pharmaceuticals AB Conjugates of biologically active molecules to functionalized polymers
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
SG10201811124YA (en) 2014-06-20 2019-01-30 Abgenomics Int Inc Her2 antibody-drug conjugates
JP6369721B2 (ja) * 2014-07-04 2018-08-08 国立大学法人 東京大学 リゾホスファチジルセリン誘導体
CN104725628B (zh) * 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
US20170368189A1 (en) 2015-01-09 2017-12-28 Ascendis Pharma Growth Disorders A/S Cnp prodrugs
EP3271401A4 (en) 2015-03-18 2018-11-21 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
CN114939174B (zh) 2015-08-14 2024-06-28 荣昌生物制药(烟台)股份有限公司 抗体-药物偶联物的共价连接子及其制备方法与应用
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
PL3400019T3 (pl) 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
CN110545850A (zh) 2017-03-10 2019-12-06 奎亚培格制药公司 可释放的缀合物
BR112020015071A2 (pt) 2018-03-09 2021-01-05 Quiapeg Pharmaceuticals Ab Conjugados de anticorpos liberáveis
WO2020053815A1 (en) * 2018-09-12 2020-03-19 Quiapeg Pharmaceuticals Ab Releasable glp-1 conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105813653A (zh) * 2013-12-19 2016-07-27 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957735B2 (en) 2018-09-12 2024-04-16 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
CN112955216A (zh) * 2018-09-12 2021-06-11 奎亚培格制药公司 可释放glp-1缀合物
CN111175387B (zh) * 2018-11-13 2022-06-07 成都康弘药业集团股份有限公司 一种米那普仑异构体的检测方法
CN111175387A (zh) * 2018-11-13 2020-05-19 成都康弘药业集团股份有限公司 一种米那普仑异构体的检测方法
CN112168820A (zh) * 2019-07-05 2021-01-05 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
CN110946844A (zh) * 2019-12-11 2020-04-03 正大制药（青岛）有限公司 一种含有艾地骨化醇的复方控释制剂
CN113456824B (zh) * 2020-03-31 2023-03-31 四川大学华西医院 一种抗肿瘤载药纳米复合材料
CN113456824A (zh) * 2020-03-31 2021-10-01 四川大学华西医院 一种抗肿瘤载药纳米复合材料
CN112316156A (zh) * 2020-10-27 2021-02-05 四川大学 具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
CN112316156B (zh) * 2020-10-27 2022-03-15 四川大学 具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
CN112402620A (zh) * 2020-12-07 2021-02-26 南开大学 肿瘤微环境还原响应性的纳米药物及其制备方法
CN112457383B (zh) * 2020-12-16 2022-06-17 阿南达 一种多肽、制备方法及其医药用途
CN112457383A (zh) * 2020-12-16 2021-03-09 南京盖斯夫医药科技有限公司 一种多肽、制备方法及其医药用途
CN112516285A (zh) * 2020-12-18 2021-03-19 中南大学 一种预防或治疗缺血/再灌注损伤的药物组合物及应用
CN112574272A (zh) * 2020-12-25 2021-03-30 中国医学科学院药用植物研究所 一种灵芝酸a衍生物的制备及其应用
CN114516921B (zh) * 2021-02-05 2023-01-06 华南理工大学 基于单链抗体片段的融合蛋白、纳米组装体及其制备方法和应用
CN114516921A (zh) * 2021-02-05 2022-05-20 华南理工大学 基于单链抗体片段的融合蛋白、纳米组装体及其制备方法和应用
CN114617876A (zh) * 2022-01-28 2022-06-14 四川大学华西医院 一种抗肿瘤联合用药物
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物
CN114886817B (zh) * 2022-06-02 2023-06-27 杭州配方师科技有限公司 一种弗来歇氏柳叶菜和酵母菌锌发酵复合物、制备方法及应用
CN114886817A (zh) * 2022-06-02 2022-08-12 杭州配方师科技有限公司 一种弗来歇氏柳叶菜和酵母菌锌发酵复合物、制备方法及应用
CN118324849A (zh) * 2022-12-22 2024-07-12 四川大学华西医院 一种抗菌肽及其制备方法和用途
CN119709677A (zh) * 2024-10-28 2025-03-28 皖西学院 一种糖基转移酶及其在制备金线莲苷中的应用
CN119709677B (zh) * 2024-10-28 2025-05-06 皖西学院 一种糖基转移酶及其在制备金线莲苷中的应用
CN119613558A (zh) * 2024-12-12 2025-03-14 东北农业大学 一种抗磺胺嘧啶纳米抗体及其应用
CN119613558B (zh) * 2024-12-12 2025-08-15 东北农业大学 一种抗磺胺嘧啶纳米抗体及其应用
CN120531651A (zh) * 2025-07-29 2025-08-26 清枫链食苏打饮品(吉林)有限公司 人参提取物、制备方法及其在美白嫩肤祛皱产品中的应用
CN120531651B (zh) * 2025-07-29 2025-09-30 清枫链食苏打饮品(吉林)有限公司 人参提取物、制备方法及其在美白嫩肤祛皱产品中的应用

Also Published As

Publication number Publication date
JP2022191304A (ja) 2022-12-27
AU2018231832A1 (en) 2019-08-08
KR20190125310A (ko) 2019-11-06
SI3592393T1 (sl) 2022-04-29
AU2024201279A1 (en) 2024-03-21
EP4011396A1 (en) 2022-06-15
US20180360974A1 (en) 2018-12-20
US11786599B2 (en) 2023-10-17
JP2020512302A (ja) 2020-04-23
WO2018163131A1 (en) 2018-09-13
JP7152408B2 (ja) 2022-10-12
EP3592393A1 (en) 2020-01-15
EP3592393B1 (en) 2021-12-01
BR112019017103A2 (pt) 2020-04-14
CA3051173A1 (en) 2018-09-13
JP7381684B2 (ja) 2023-11-15
US20230381323A1 (en) 2023-11-30
DK3592393T3 (da) 2022-03-07

Similar Documents

Publication Publication Date Title
US20230381323A1 (en) Releasable conjugates
US11559482B2 (en) Biodegradable polyethylene glycol based water-insoluble hydrogels
CA2843875C (en) High-loading water-soluble carrier-linked prodrugs
US11116849B2 (en) Hydrogel-linked prodrugs releasing tagged drugs
US20140243254A1 (en) Polymeric Hyperbranched Carrier-Linked Prodrugs
US20230123784A1 (en) Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels
HK40067052A (en) Releasable conjugates
HK40012935B (en) Releasable conjugates
HK40012935A (en) Releasable conjugates
HK40045395A (en) Biodegradable polyethylene glycol based water-insoluble hydrogels

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191206